Follow
Laura de-la-Puente-Ovejero (ORCID 0000-0002-0835-7069)
Laura de-la-Puente-Ovejero (ORCID 0000-0002-0835-7069)
Verified email at cnio.es
Title
Cited by
Cited by
Year
An overview of alternative splicing defects implicated in myotonic dystrophy type I
A López-Martínez, P Soblechero-Martín, L de-la-Puente-Ovejero, ...
Genes 11 (9), 1109, 2020
842020
Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies
P Soblechero‐Martín, A López‐Martínez, L de la Puente‐Ovejero, ...
Neuropathology and Applied Neurobiology 47 (6), 711-723, 2021
292021
Structure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation
S García-Alonso, P Mesa, L de la Puente Ovejero, G Aizpurua, ...
Molecular cell 82 (18), 3438-3452. e8, 2022
182022
Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screening
P Soblechero-Martín, E Albiasu-Arteta, A Anton-Martinez, ...
Scientific Reports 11 (1), 18188, 2021
112021
Building insights into CDC37-RAF1 interaction: an opportunity for design new strategies to treat KRAS driven tumors.
L De-la-Puente-Ovejero, G Aizpurua, C Gonzalez Lechuga, P Mesa, ...
ibjournals 1 (0001-e0049), e00037, 2022
2022
In vitro study of cellular, molecular and functional mechanisms underlying pelvic floor disorders
J Medina-Polo, AI Flores, MJ Perez-Lorenzo, A Alcazar-Garrido, ...
European Urology Open Science 19, e1614, 2020
2020
The system can't perform the operation now. Try again later.
Articles 1–6